T. Jaquin

Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity

J. Johnston, H. Kwok, A. Kissenpfennig, 2011, Molecular Cancer.

Antibody Targeting of Cathepsin S Inhibits Angiogenesis and Synergistically Enhances Anti-VEGF

J. Johnston, C. Scott, Diana Kuehn, 2010, PloS one.

Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343

L. Matis, J. Schüler, S. Berger, 2019, Clinical Cancer Research.

Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas.

J. Johnston, H. Kwok, C. Scott, 2012, Biochimie.

The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner

H. Lelièvre, B. Bossenmaier, V. Blanc, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Antibody-Mediated Inhibition of Cathepsin S Blocks Colorectal Tumor Invasion and Angiogenesis

J. Johnston, B. Walker, C. Scott, 2009, Clinical Cancer Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Costimulatory T-cell engagement by PRS-343, a CD137 (4-1BB)/HER2 bispecific, leads to tumor growth inhibition and TIL expansion in a humanized mouse model

J. Schüler, S. Berger, T. Jaquin, 2016 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.